Sun Pharma expects single-digit decline in consolidated revenues for FY18

04 Sep 2017 Evaluate

Sun Pharmaceutical Industries expects a single-digit decline in consolidated revenues for FY18 since the short-term outlook continues to be challenging as the US generics industry is facing rapidly changing market dynamics.

The increased competitive intensity and customer consolidation is leading to pressure on pricing, while continued delay in approvals from the Halol facility is also impacting the company’s working.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.


Sun Pharma Inds. Share Price

1782.80 -14.45 (-0.80%)
16-Dec-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2085.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×